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OBJECTIVES The purpose of this study was to assess safety and efficacy of enhanced external counterpul-
sation (EECP).
BACKGROUND Case series have shown that EECP can improve exercise tolerance, symptoms and myocardial
perfusion in stable angina pectoris.
METHODS A multicenter, prospective, randomized, blinded, controlled trial was conducted in seven
university hospitals in 139 outpatients with angina, documented coronary artery disease
(CAD) and positive exercise treadmill test. Patients were given 35 h of active counterpulsa-
tion (active CP) or inactive counterpulsation (inactive CP) over a four- to seven-week period.
Outcome measures were exercise duration and time to $1-mm ST-segment depression,
average daily anginal attack count and nitroglycerin usage.
RESULTS Exercise duration increased in both groups, but the between-group difference was not
significant (p . 0.3). Time to $1-mm ST-segment depression increased significantly from
baseline in active CP compared with inactive CP (p 5 0.01). More active-CP patients saw
a decrease and fewer experienced an increase in angina episodes as compared with
inactive-CP patients (p , 0.05). Nitroglycerin usage decreased in active CP but did not
change in the inactive-CP group. The between-group difference was not significant (p . 0.7).
CONCLUSIONS Enhanced external counterpulsation reduces angina and extends time to exercise-induced
ischemia in patients with symptomatic CAD. Treatment was relatively well tolerated and free
of limiting side effects in most patients. (J Am Coll Cardiol 1999;33:1833–40) © 1999 by the
American College of Cardiology
Current treatment for angina, including drug therapy (1)
with nitrates, beta-adrenergic blocking agents and calcium
channel blocking agents either as single agents or in com-
bination, or revascularization by either percutaneous trans-
luminal coronary angioplasty (2) or coronary artery bypass
See page 1841
grafting (CABG) (3), can be effective in a significant
number of patients. However, side effects of medications,
coronary vasculature not amenable to either initial or repeat
revascularization or diminishing treatment benefit may oc-
cur over time.
The search for more therapeutic options for patients with
chronic angina has yielded a wide range of new treatment
modalities in various stages of clinical evaluation, including
transmyocardial laser revascularization (4), minimally inva-
sive bypass surgery (5), spinal cord stimulation (6), transcu-
taneous electrical nerve stimulation (7) and external coun-
terpulsation (CP) (8).
In the U.S., experience with enhanced external CP
(EECP), a modified version of external CP, is based on a
series of case studies (9,10) in which EECP was successful
in relieving angina, improving exercise tolerance and reduc-
ing reversible perfusion defects in radionuclide scans. De-
spite the use of external CP in its various designs over the
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past 30 years (11), no controlled trial has been conducted to
determine whether the procedure is effective and safe for
reducing angina pectoris in patients with coronary artery
disease (CAD).
METHODS
Objectives. The multicenter study (MUST)-EECP trial
was a randomized, placebo (sham) controlled, multicenter
trial designed to evaluate EECP in patients with angina and
documented CAD. Treatment effect was determined by
comparing changes in exercise treadmill test (ETT) param-
eters (exercise duration, time to $1-mm ST-segment de-
pression), symptoms (frequency of anginal episodes and
nitroglycerin [NTG] usage between groups).
Subjects. The MUST-EECP trial was conducted at seven
medical centers in the U.S. (see Appendix). Approximately
500 patients with chronic stable angina were considered for
inclusion, of whom 139 were randomized between May
1995 and May 1997. Main reasons for nonenrollment
included failure to satisfy inclusion/exclusion criteria, and
patient refusal. To be eligible, patients had to meet the
following criteria: 1) be between 21 and 81 years of age; 2)
have symptoms consistent with Canadian Cardiovascular
Society Classification angina levels I, II or III; 3) have
documented evidence of CAD and 4) have an ETT positive
for ischemia.
Evidence of CAD required at least one of the three
following criteria: one or more angiographically proved
stenosis .70% in at least one major coronary artery; history
of myocardial infarction (MI) documented by characteristic
creatine kinase elevation and development of Q waves on
the electrocardiogram or positive nuclear exercise stress test
for MI or ischemia.
Prospective subjects were excluded if they had the fol-
lowing: MI or CABG in the preceding three months,
cardiac catheterization in the preceding two weeks, unstable
angina, overt congestive heart failure or a left ventricular
ejection fraction #30%, significant valvular heart disease,
blood pressure .180/100 mm Hg, permanent pacemaker or
implantable defibrillator, nonbypassed left main stenosis
greater than 50%, severe symptomatic peripheral vascular
disease, history of varicosities, deep vein thrombosis, phle-
bitis or stasis ulcer, bleeding diathesis, warfarin use with
International Normalized Ratio .2.0, atrial fibrillation or
frequent ventricular premature beats that would interfere
with EECP triggering or baseline electrocardiographic ab-
normalities that would interfere with interpretation of
exercise electrocardiogram. Also excluded were pregnant
women, women of childbearing potential, subjects unable to
undergo treadmill testing and subjects enrolled in a cardiac
rehabilitation program or in another research program.
The study was approved by the Institutional Review
Boards at participating institutions and conducted in accor-
dance with the Declaration of Helsinki. Enrollment was
conditional upon subjects giving written informed consent.
Study organization. The study was coordinated centrally
by a Core Laboratory. When an eligible patient was
identified at a study center, his or her characteristics were
communicated to the Study Coordinator at the Core
Laboratory where all eligibility criteria were reviewed. Eli-
gible subjects were assigned at random to receive either
active CP or placebo delivered as sham therapy in the form
of inactive CP as described below. Treatment allocation was
based on random codes generated in blocks of 10, with
whole blocks assigned to one center, to ensure that patients
were assigned equally to each treatment group at each center
(12). The same number of random codes was assigned to
each treatment group. Assignment was transmitted only to
personnel administering EECP at each study center. Study
personnel involved in collecting and processing data at the
study centers and at the Core Laboratory remained blinded
for the duration of the study. To prevent study subjects from
recognizing any observable differences between sham and
active treatment, appointments were scheduled so as to
minimize any opportunities for study subjects in one group
to discuss their experience either with other patients under-
going EECP or with MUST-EECP subjects in the other
group. The Study Coordinator at the Core Laboratory was
notified of adverse experiences and reported them to an
independent data and safety monitoring committee.
Study design. Before randomization, medical history,
physical examination and a baseline ETT were performed.
The baseline ETT used a standard or a modified Bruce
protocol and was performed within four weeks of treatment
initiation. All medications (except on-demand NTG) re-
mained unchanged for the duration of the study. Once
randomized, patients underwent 35 h of either active CP or
inactive CP. Treatment sessions, each lasting 1 h, could be
given once or twice per day. At each treatment session, vital
signs were recorded, lower extremities were examined for
areas of redness or ecchymosis, adverse experiences were
reported and study subjects reported the number of anginal
episodes experienced and NTG tablets taken during the
preceding 24-h period. An adverse reaction was defined as
the development of any new symptom or complaint from
the time of randomization. Within one week after comple-
tion of 35 treatment sessions, a posttreatment ETT was
Abbreviations and Acronyms
CABG 5 coronary artery bypass grafting
CAD 5 coronary artery disease
CP 5 counterpulsation
EECP 5 enhanced external counterpulsation
ETT 5 exercise treadmill test
MI 5 myocardial infarction
MUST 5 multicenter study
NO 5 nitric oxide
NTG 5 nitroglycerin
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performed. Baseline and posttreatment ETT were per-
formed by personnel not aware whether the patient was in
the active-CP or the inactive-CP group.
Enhanced external counterpulsation. Enhanced external
counterpulsation equipment was supplied by the manufac-
turer, Vasomedical (Westbury, New York). The equipment
consists of an air compressor, a console, a treatment table
and two sets of three cuffs. Before a treatment session, these
cuffs are wrapped around the patient’s legs, one set on each
leg. Using compressed air, pressure is applied via the cuffs to
the patient’s lower extremities in a sequence synchronized
with the cardiac cycle. In early diastole, pressure is applied
sequentially from the lower legs to the lower and upper
thighs to propel blood back to the heart. This results in an
increase of arterial blood pressure and retrograde aortic
blood flow during diastole (diastolic augmentation). At
end-diastole, air is released instantaneously from all the cuffs
to remove the externally applied pressure, allowing the
compressed vessels to reconform, thereby reducing vascular
impedance. The pressures that can be applied to the cuffs
range from 0 to 350 mm Hg. In MUST-EECP, the
pressure applied to the cuffs was 300 mm Hg in the
active-CP group and 75 mm Hg in the control group,
enough to preserve the appearance and feel of an EECP
application, but insufficient to alter measurably the patient’s
blood pressure. Blood pressure changes are monitored by
finger plethysmography. To assess the hemodynamic effect
of EECP, two ratios are computed electronically, using the
systolic and diastolic peak pressures or the area under the
systolic and diastolic curves. Ratios greater than one corre-
spond to diastolic values greater than systolic values. In
MUST-EECP, the means of patients’ diastolic to systolic
pressure and area under the curve ratios achieved were
1.41 6 0.51 (mean 6 SD) and 1.59 6 0.6, respectively, in
active CP, showing effective diastolic augmentation.
Changes in these parameters were undetectable in inactive
CP, confirming the lack of hemodynamic effect in the latter
group. All other aspects of treatment delivery were the same
in both groups.
End points. Tracings of each ETT from each study center
were sent to the Core Laboratory where exercise duration (s)
and time to $1-mm ST-segment depression (s) were
recorded by personnel unaware of the treatment assignment
of each patient and whether the ETT was baseline or
posttreatment. Exercise duration was defined as elapsed
time from the initiation of exercise to the beginning of the
recovery period. Time to ST-segment depression was de-
fined as the elapsed time from initiation of exercise to the
occurrence of horizontal or down-sloping ST-segment de-
pression $1 mm, 80 ms after the J point, persisting for at
least three consecutive beats.
The average frequency of angina episodes per day (angina
counts) was computed by dividing the total number of
angina episodes reported at three successive treatment
sessions by the number of days in which the sessions took
place. Whenever two sessions were conducted on the same
day, only angina episodes reported for the first session were
used, because the second session covered the same 24-h
period as the first session of that day. The first three sessions
(i.e., sessions 1 to 3) were considered as the baseline period.
In addition, the difference in angina counts between base-
line and at end-treatment were calculated as percentage
change for each patient in the active- and inactive-CP
groups and were classified into the following categories:
50%1 improvement, 25% to 49% improvement, 0 to 24%
improvement, 1% to 25% worsening, 26% to 50% worsen-
ing, 51% to 100% worsening and .100% worsening.
Patients with no episodes at the first three sessions were
considered as having no change (0%) if they also had no
episodes at other periods, and were considered as worsening
by 100% or more if they had episodes at other periods.
Statistical analyses. On the basis of a between-patient
standard deviation of 87 s in exercise duration, there was
80% power to detect a 45-s difference in exercise duration
between the two study groups using a two-sided test with a
0.05 level of significance. The primary efficacy analyses for
ETT parameters were performed on an observed case basis
using the intention to treat population. Changes in exercise
duration and time to $1-mm ST-segment depression from
baseline to posttreatment ETT were calculated for each
subject and compared between treatment groups. An anal-
ysis of variance with treatment group as a main effect and
treatment site as a blocking factor was then made. The
method used for computing angina counts took into account
the varying total treatment time among patients many of
whom, for the sake of convenience, underwent two treat-
ment sessions daily for at least part of the treatment course
(see End Point section). Two analyses of angina counts were
performed. An analysis of variance, on rank transformed
data by treatment center, was applied to changes in angina
counts from baseline to follow-up. Also, the difference
between the two treatment groups with respect to percent-
age change in angina counts was computed for the entire
intention to treat population (all randomized patients) and
for those patients with $34 sessions (i.e., for patients having
completed EECP treatment). The difference between the
two treatment groups with respect to the percent change in
each parameter was tested using a Cochran-Mantel-
Haenszel chi-square test for ordered categories, stratified by
treatment center. Results are presented as adjusted means
(least-squares), calculated to accommodate any imbalance in
the number of patients in each group among treatment
centers. This conforms to the analysis of variance model
using treatment center as a blocking factor. The analysis of
average usage of on-demand NTG tablets per day (NTG
count) was conducted in the same manner as for the analysis
of angina counts.
Adverse experiences. The number of patients reporting
adverse events was compared between groups using a
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chi-square test. A chi-square test was also used to compare
the number of sessions where leg discomfort was reported.
RESULTS
Patient enrollment. One hundred thirty-nine patients
were randomized in MUST-EECP. Patient disposition is
shown in Figure 1.
Exercise duration data were available for 57 subjects in
the active-CP and 58 in the inactive-CP group. Fourteen
subjects in active CP were not evaluable for exercise dura-
tion: 4 had protocol violations, 7 withdrew because of
adverse experiences and 3 dropped out for personal reasons.
In the inactive-CP group, 8 subjects were not evaluable for
exercise duration. Seven of these had protocol violations,
and one dropped out because of an adverse experience.
Evaluable data for time to $1-mm ST-segment depression
were available for 56 subjects in each study group. Digoxin
use invalidated time to ST-segment depression analysis in
one subject in the active-CP group and two in the
inactive-CP group.
Patient characteristics. The characteristics of the random-
ized groups were similar, although a higher percentage of
patients in the active-CP group had a history of previous MI
and suffered from angina for a longer period of time (Table
1). Antianginal treatment was similar for both groups
(Table 1). More than 70% of patients in each group had
Canadian Cardiovascular Society Classification class II or
III and over 70% of each group had undergone prior CABG
or angioplasty.
Efficacy. EXERCISE TREADMILL TEST. Exercise duration
was 426 6 20 s at baseline and 470 6 20 s posttreatment in
the active-CP group. In the inactive-CP group, exercise
Figure 1. Patient disposition. CP 5 counterpulsation.
Table 1. Patient Characteristics
Inactive
CP
Active
CP
p
Values
n 66 71
Age (mean 6 SD) 62 6 9 yr 64 6 9 yr . 0.1
Male 58 (87.9%) 61 (85.9%) . 0.8
Race . 0.5
White 49 (74.2%) 55 (77.5%)
Black 2 (3.0%) 3 (4.2%)
Hispanic 10 (15.2%) 5 (7.0%)
Asian 3 (4.5%) 5 (7.0%)
Other 2 (3.0%) 3 (4.2%)
CV history
CCSC . 0.9
I 17 (25.8%) 19 (26.8%)
II 34 (51.5%) 35 (49.3%)
III 15 (22.7%) 17 (23.9%)
Angina years
(mean 6 SD)
4.5 6 4.06 8.56 6 7.88 , 0.01
Previous MI 27 (40.9%) 40 (56.3%) , 0.05
Previous CABG 25 (37.9%) 33 (46.5%) . 0.3
Previous PTCA 22 (33.3%) 27 (38.0%) . 0.5
Residual vessel
disease
. 0.1
0 5 (7.6%) 5 (7.0%)
1 23 (34.8%) 21 (29.6%)
2 17 (15.8%) 19 (26.8%)
3 9 (13.6%) 21 (29.6%)
No data 12 (18.2%) 5 (7.0%)
CV medications . 0.8
Nitrates 54 (81.8%) 56 (78.9%)
ASA 60 (90.9%) 32 (87.3%)
CCB 36 (54.5%) 44 (62.0%)
BB 51 (77.3%) 50 (70.4%)
Lipid-lowering agents 33 (50.0%) 44 (62.0%)
Angina years 5 years since diagnosis; ASA 5 acetylsalicylic acid taken as an
antithrombotic; BB 5 beta-blocker; CABG 5 coronary artery bypass grafting;
CCB 5 calcium channel blocker; CCSC 5 Canadian Cardiovascular Society
functional classification for angina; CP 5 counterpulsation; CV 5 cardiovascular;
MI 5 myocardial infarction; PTCA 5 percutaneous transluminal coronary angio-
plasty.
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duration was 432 6 22 s at baseline and 464 6 22 s
posttreatment (Table 2). There was no significant difference
between groups in change in exercise duration from baseline
to posttreatment (adjusted mean: active CP: 42 6 11 s vs.
inactive CP: 26 6 12 s; p . 0.3).
Time to $1-mm ST-segment depression was 337 6 18 s
at baseline and 379 6 18 s posttreatment in the active-CP
group. In the inactive-CP group, time to $1-mm ST-
segment depression was 326 6 21 s at baseline and 330 6
20 s posttreatment (Table 2). There was a significant
difference between groups in the change in time to exercise-
induced ischemia from baseline to posttreatment (adjusted
mean: active CP: 37 6 11 s vs. inactive CP: 24 6 12 s; p 5
0.01).
ANGINA COUNTS. In the intention to treat analysis, angina
counts were 0.76 6 0.15 at baseline and 0.55 6 0.27
posttreatment in the active-CP group. In the inactive-CP
group, angina counts were 0.76 6 0.13 at baseline and
0.77 6 0.2 posttreatment. The difference between groups in
the change in angina counts from baseline to posttreatment
showed a trend to statistical significance (adjusted mean:
active CP: 20.11 6 0.21 vs. inactive CP: 0.13 6 0.22; p ,
0.09). In patients who completed $34 sessions, angina
counts were 0.72 6 0.14 at baseline and 0.57 6 0.38
posttreatment in the active-CP group. In the inactive-CP
group, angina counts were 0.77 6 0.14 at baseline and
0.76 6 0.22 posttreatment. The difference between groups
in the change in angina counts from baseline was statistically
significant (adjusted mean: active CP: 20.033 6 0.27 vs.
inactive CP: 0.15 6 0.27; p , 0.035). A similar number of
patients in each group showed a 0 to 25% level of improve-
ment, but more patients reported a .50% improvement in
angina frequency, and fewer worsened in the active-CP
group compared with the inactive-CP group (p , 0.05,
Table 3).
NITROGLYCERIN USAGE. In the intention to treat analysis,
NTG usage was 0.47 6 0.13 at baseline and 0.19 6 0.07
posttreatment in the active-CP group. In the inactive-CP
group, NTG usage was 0.51 6 0.15 at baseline and 0.45 6
0.19 posttreatment. The difference between groups in
change in NTG usage from baseline to posttreatment was
not significant (adjusted mean: active CP: 20.32 6 0.12 vs.
inactive CP: 20.10 6 0.12; p . 0.1). In patients who
completed $34 sessions, NTG usage was 0.39 6 0.11 at
baseline and 0.12 6 0.04 posttreatment in the active-CP
group. In the inactive-CP group, NTG usage was 0.56 6
0.17 at baseline and 0.43 6 0.21 posttreatment. The
difference between groups in this parameter from baseline
to posttreatment was not significant (adjusted mean:
active CP: 20.32 6 0.15 vs. inactive CP: 20.19 6 0.14;
p . 0.1).
ADVERSE EXPERIENCES. Both treatment groups, in re-
sponse to queries, reported a relatively high incidence of
adverse events at each treatment session. This is not
surprising, because patients were questioned daily by re-
search nurses about any adverse reaction experienced since
the previous session. More patients in the active-CP group
reported adverse events than in the inactive-CP group: 39
(55%) versus 17 (26%), p , 0.001. Ten of the 25 events
reported by the 17 patients in the inactive-CP group were
considered device-related, involving either the skin, lower
legs or back. Thirty-seven of the 70 events reported by the
39 patients in the active-CP group were considered device-
Table 2. Exercise Treadmill Test
Inactive CP Active CP
Between-Group
p Valuen Pre-CP Post-CP p Value n Pre-CP Post-CP p Value
Exercise duration (s) 58 432 6 22 464 6 22 , 0.03 57 426 6 20 470 6 20 , 0.001 , 0.31
Time to $1-mm
ST-segment depression (s)
56 326 6 21 330 6 20 , 0.74 56 337 6 18 379 6 18 , 0.002 5 0.01
Duration in seconds, mean 6 SEM.
Pre-CP: baseline, before counterpulsation; Post-CP: follow-up, postcounterpulsation. p values are computed based on adjusted change in duration from baseline to follow-up.
Table 3. Angina Counts
Median
Improvement Worsening
p
Value501% 25%–49% 0%–24% 1%–25% 26%–50% 51%–100% 1001%
Intention to treat
Inactive CP 66 0% 21 3 28 2 2 4 6
Active CP 71 220% 32 1 33 0 0 2 3 , 0.05
$34 sessions
Inactive CP 59 0% 19 2 24 0 2 5 7
Active CP 57 250% 29 1 23 0 0 0 4 , 0.02
Categories of change are expressed in percent versus baseline. Daily average of self-reported episodes of angina pectoris are computed over three 24-h periods. p values are
calculated for between-group differences using a Cochran-Mantel-Haenszel chi-square test for ordered categories stratified by treatment center.
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related. The remaining complaints in each group were
considered minor and not directly related to treatment
(Table 4). Leg discomfort was reported in 11.6 6 22.7% of
active-CP sessions and 4.9 6 18.7% of active-CP sessions
(p 5 0.06). Although 47 of the 95 events reported by both
groups combined were considered device-related, only five
patients withdrew from the study due to leg complaints
(e.g., pain, abrasion).
DISCUSSION
Effect on exercise treadmill test. The MUST-EECP trial
confirms that EECP can reduce exercise-induced ischemia
in patients with symptomatic CAD. The lack of a signifi-
cant treatment effect on exercise duration despite reduction
in other measures of ischemia has been seen in other clinical
trials involving antianginal agents (13,14). Training effect or
the fact that most study patients were limited by nonanginal
symptoms such as fatigue or shortness of breath on the
treadmill tests may have produced a fixed exercise duration
and account for this observation. Moreover, EECP might
be less likely to extend exercise capacity when added to
background treatments of antianginal drugs and coronary
revascularization than if such treatments were not in place.
There was, however, an increase in time to exercise-induced
ischemia, a more objective parameter of treatment effect, in
the active-CP group, and the between-group difference was
significant.
Effect on angina counts and NTG usage. A trend in
angina reduction with EECP was seen in the intention to
treat analysis and became significant when the analysis
included only those subjects completing at least 34 sessions.
This observation suggests that a certain number of treat-
ment hours are required to maximize the antianginal benefit
of this device (see Mechanisms of Action section). Al-
though NTG usage dropped in the active-CP group, no
between-group difference was noted. The wide range of
NTG tablets taken by both groups and the common
practice of patients with this degree of angina of taking
NTG prophylactically, a habit unlikely to be changed over
the course of a seven-week study, may explain this finding.
Mechanisms of action. The mechanisms underlying the
effects of EECP have been under investigation for many
years. Acute hemodynamic improvement simulating the
effects of intra-aortic balloon CP can be achieved (15), and
a multicenter randomized trial in patients with acute MI
and heart failure demonstrated that external CP reduced
morbidity and mortality (16). The use of this early device to
treat angina also suggested benefit (17,18), but variations in
treatment protocol produced variable results.
Reasons for continued relief of angina beyond the acute
hemodynamic beneficial effects of EECP treatment as
described in case series (8–10) are unclear. Increased
transmyocardial pressure gradients for the prescribed 35
sessions could open collaterals (19,20). Chronic exposure of
the coronary and peripheral arterial bed to the augmented
blood flow and increased shear forces produced by EECP
could lead to increased endothelial cell production of nitric
oxide (NO) and prostacyclin, powerful mediators of vaso-
dilation. Supporting this notion is the recent observation
that sustained exercise in dogs increased endothelial NO
synthase gene expression and coronary vascular NO produc-
tion (21). Increased blood flow may regulate the elaboration
of a variety of paracrine substances that participate in
vascular remodeling and reactivity (22). Consistent with
these hypotheses, other strategies targeted to improve
endothelial-dependent vasodilation, such as estrogen re-
placement in postmenopausal women (23) and low density
lipoprotein lowering in hypercholesterolemic patients (24),
have also been shown to decrease ischemia.
Clinical implications. Because coronary disease is a
chronic condition, and long-term survival is extended with
secondary prevention, practitioners see patients with recur-
rent angina despite therapy with anti-ischemic agents and
coronary revascularization. Most patients enrolled in
MUST-EECP fall into this category. In addition, there are
many patients who are inoperable, at high risk for operative
Table 4. Adverse Experiences
Inactive CP
(n 5 66)
Active CP
(n 5 71)
p Valuen (%) n (%)
Patients with AE 17 (25.8) 39 (54.9) , 0.001
Adverse experiences—
non–device related
Viral syndrome 0 1 . 0.5
Anxiety 0 2 5 0.5
Dizziness 1 3 . 0.5
Tinnitus 0 1 . 0.5
GI disturbances 1 1 . 0.5
Headache 0 1 . 0.5
Blood pressure change 1 1 . 0.5
Epistaxis 0 2 5 0.5
Angina 1 1 . 0.5
Other chest pain 3 7 5 0.3
A/V arrhythmia 3 9 . 0.2
Heart rate change
(sinusal)
3 0 5 0.1
Respiratory 2 4 . 0.5
Total 15 33 , 0.005
Adverse experiences—
device related
Paresthesia 1 2 . 0.5
Edema, swelling 0 2 5 0.5
Skin abrasion, bruise,
blister
2 13 5 0.005
Pain (legs, back) 7 20 5 0.01
Total 10 37 , 0.001
Some patients reported more than one adverse experience (AE), hence total AE
exceed numbers of patients reporting AE. p value: Fisher exact test.
A/V 5 atrioventricular; CP 5 counterpulsation; GI 5 gastrointestinal.
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complications or postoperative failure, whose coronary anat-
omy is not readily amenable to invasive procedures or who
have comorbid states associated with excessive risk. For such
patients, EECP could extend the range of treatment op-
tions.
Limitations. The design of MUST-EECP has several
limitations. The use of a sham method to serve as a placebo
control is imperfect but is used often in device- or
procedure-related clinical trials (25,26). The fact that some
patients in the sham-treated group reported lower leg and
skin adverse reactions suggests that sham CP simulated
active treatment as intended. Although care was taken to
prevent study participants from witnessing other patients
receiving EECP, it is possible that some patients in MUST-
EECP guessed correctly their form of treatment. Further-
more, it was impossible to blind personnel applying the
EECP treatment, leaving open the possibility that the form
of treatment could have been suggested inadvertently. Al-
though angina counts and NTG usage were assessed using
the subjects’ recollection, patients were only asked to recall
whether these events had occurred in the 24-h period
preceding each treatment session. Most treatments for
angina have been the subject of cost-effectiveness analyses
and, at the present time, no such data are available for
EECP. In addition, MUST-EECP examines only the
immediate effect of treatment. Its long-term effects on
symptoms and clinical events are not known.
Conclusions. The MUST-EECP trial, the first random-
ized controlled study to evaluate EECP, indicates that
enhanced external CP can reduce angina and extend the
time to ischemia on ETT in patients with symptomatic
CAD. The treatment was relatively well tolerated and free
of limiting side effects in most patients.
APPENDIX
MUST-EECP Study Centers
Columbia-Presbyterian Medical Center, Columbia Univer-
sity (New York, New York); Moffit-Long Hospital, Uni-
versity of California at San Francisco (San Francisco,
California); Yale University School of Medicine (New
Haven, Connecticut); Beth Israel Deaconess Medical Cen-
ter, Harvard University (Boston, Massachusetts); Grant/
Riverside Methodist Hospitals (Columbus, Ohio); Presby-
terian University Hospital, University of Pittsburgh Medical
Center (Pittsburgh, Pennsylvania); and Loyola University
Medical Center (Maywood, Illinois).
MUST-EECP Trial Coordinators
Columbia-Presbyterian Medical Center: Christine Con-
stantine, RN; Patricia Blowers, RN; Christopher Kaszubski,
RN; Patricia Pugni, RN. Moffit-Long Hospital: Kim
Prouty, RN; Olga Dimitratos, RN; Xian-Hong Shu, MD.
Yale University School of Medicine: Poonamma Chanada,
MD; Sanila Rehmatullah, MD; Neil Jairath. Beth Israel
Deaconess Hospital: Carol McKenna, RN; Peggy
McGowan-Gump, RN. Grant/Riverside Methodist Hospi-
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